STOCK TITAN

Caligan exits Evolus (EOLS), amended filing shows 0% ownership

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Evolus, Inc. received an updated ownership report from Caligan Partners LP and David Johnson showing they no longer beneficially own any of its common stock. The filing states each reporting person has 0 shares with sole or shared voting and dispositive power, representing 0.0% of the common stock class as of the reported date. The reporters also certify the securities were acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Evolus.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Caligan Partners LP
Signature:/s/ David Johnson
Name/Title:David Johnson, Managing Partner
Date:02/17/2026
David Johnson
Signature:/s/ David Johnson
Name/Title:David Johnson, Managing Partner
Date:02/17/2026

FAQ

What does the Caligan Schedule 13G/A filing mean for Evolus (EOLS)?

It shows Caligan Partners LP and David Johnson now report beneficial ownership of 0 Evolus common shares, or 0.0% of the class. This indicates they are no longer 5% or greater shareholders under SEC reporting rules.

Who are the reporting persons in the Evolus (EOLS) Schedule 13G/A?

The reporting persons are Caligan Partners LP and David Johnson. Caligan served as investment manager to certain funds and accounts holding Evolus common stock, and Johnson is Caligan’s Managing Partner and Managing Member of its general partner.

How many Evolus (EOLS) shares does Caligan now beneficially own?

Caligan reports beneficial ownership of 0.00 Evolus common shares. The filing lists 0.00 sole voting power, 0.00 shared voting power, 0.00 sole dispositive power, and 0.00 shared dispositive power, resulting in 0.0% of the class.

What percentage of Evolus (EOLS) does David Johnson report owning?

David Johnson reports beneficial ownership of 0.00 Evolus common shares, representing 0.0% of the outstanding common stock. He has no sole or shared voting or dispositive power over Evolus shares according to the ownership table.

Why is this Evolus (EOLS) Schedule 13G/A labeled Amendment No. 2?

It is an amended beneficial ownership statement updating prior Schedule 13G reports. Amendment No. 2 reflects that the reporting persons’ holdings have changed so they now own 5 percent or less of the Evolus common stock class.

What business purpose does Caligan state for holding Evolus (EOLS) shares?

They certify the securities were acquired and are held in the ordinary course of business. The filing states they were not acquired or held to change or influence control of Evolus, nor in connection with any transaction having that purpose or effect.
Evolus

NASDAQ:EOLS

EOLS Rankings

EOLS Latest News

EOLS Latest SEC Filings

EOLS Stock Data

278.73M
53.54M
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
NEWPORT BEACH